Is the W.A.I.T. indicator making access to medicines worse?

▤ Summary

This article examines whether Europe’s W.A.I.T. indicator is still useful for measuring patient access to medicines. Cem Zorlular argues that the metric has become too blunt to reflect the many ways patients actually obtain treatments across markets. He warns that the index may discourage investment in countries where practical access routes already exist. The piece frames the issue as a broader policy and commercial access debate in pharma rather than a company-specific event.

▦ Linked Companies